文献速递医学人工智能与信息学流行病学与生物统计

机器学习聚类分析重新定义窦性心律与房颤心衰患者的β受体阻滞剂反应

Redefining β-blocker response in heart failure patients with sinus rhythm and atrial fibrillation: a machine learning cluster analysis.
PubMed 文献 · Lancet · 2021-08-30

本研究基于九项双盲随机安慰剂对照试验的个体患者数据,应用神经网络变分自编码器和层次聚类,在射血分数降低的心衰患者中识别β受体阻滞剂疗效不同的亚群。窦性心律患者多数聚类显示一致的死亡率获益,但一个老年轻症状聚类无显著疗效;房颤患者中一个年轻低危聚类显示显著死亡率降低。

要点

  • 窦性心律心衰患者多数聚类从β受体阻滞剂获得一致死亡率获益。
  • 窦性心律中老年轻症状聚类未见显著β受体阻滞剂疗效。
  • 房颤患者中一个年轻低危聚类显示β受体阻滞剂显著降低死亡率。

核心结论

  • 基于人工智能的聚类方法能够区分心衰伴射血分数降低患者对β受体阻滞剂的预后反应差异。
  • 窦性心律患者中存在β受体阻滞剂疗效欠佳的亚群,而房颤患者中存在β受体阻滞剂可降低死亡率的亚群。

研究设计与样本

  • 研究 pooled 九项双盲、随机、安慰剂对照的β受体阻滞剂试验的个体患者数据。
  • 采用神经网络变分自编码器和层次聚类,按心电图心律分层,意向性治疗分析全因死亡率。
  • 聚类数目和维度客观确定,采用留一试验法验证,研究前瞻性注册于ClinicalTrials.gov(NCT00832442)和PROSPERO(CRD42014010012)。

临床怎么用

  • 对于心衰伴射血分数降低患者,可参考聚类特征识别β受体阻滞剂可能获益不佳的窦性心律亚群。
  • 房颤心衰患者中,符合年轻、低死亡风险特征的聚类可能从β受体阻滞剂治疗中获益。

局限性

  • 研究基于pooled临床试验数据,结论需在更广泛真实世界人群中验证。
  • 聚类分析为观察性探索,不能完全排除未测量混杂因素的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Mortality remains unacceptably high in patients with heart failure and reduced left ventricular ejection fraction (LVEF) despite advances in therapeutics. We hypothesised that a novel artificial intelligence approach could better assess multiple and higher-dimension interactions of comorbidities, and define clusters of β-blocker efficacy in patients with sinus rhythm and atrial fibrillation. METHODS: Neural network-based variational autoencoders and hierarchical clustering were applied to pooled individual patient data from nine double-blind, randomised, placebo-controlled trials of β blockers. All-cause mortality during median 1·3 years of follow-up was assessed by intention to treat, stratified by electrocardiographic heart rhythm. The number of clusters and dimensions was determined objectively, with results validated using a leave-one-trial-out approach. This study was prospectively registered with ClinicalTrials.gov (NCT00832442) and the PROSPERO database of systematic reviews (CRD42014010012). FINDINGS: 15 659 patients with heart failure and LVEF of less than 50% were included, with median age 65 years (IQR 56-72) and LVEF 27% (IQR 21-33). 3708 (24%) patients were women. In sinus rhythm (n=12 822), most clusters demonstrated a consistent overall mortality benefit from β blockers, with odds ratios (ORs) ranging from 0·54 to 0·74. One cluster in sinus rhythm of older patients with less severe symptoms showed no significant efficacy (OR 0·86, 95% CI 0·67-1·10; p=0·22). In atrial fibrillation (n=2837), four of five clusters were consistent with the overall neutral effect of β blockers versus placebo (OR 0·92, 0·77-1·10; p=0·37). One cluster of younger atrial fibrillation patients at lower mortality risk but similar LVEF to average had a statistically significant reduction in mortality with β blockers (OR 0·57, 0·35-0·93; p=0·023). The robustness and consistency of clustering was confirmed for all models (p<0·0001 vs random), and cluster membership was externally validated across the nine independent trials. INTERPRETATION: An artificial intelligence-based clustering approach was able to distinguish prognostic response from β blockers in patients with heart failure and reduced LVEF. This included patients in sinus rhythm with suboptimal efficacy, as well as a cluster of patients with atrial fibrillation where β blockers did reduce mortality. FUNDING: Medical Research Council, UK, and EU/EFPIA Innovative Medicines Initiative BigData@Heart.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Karwath A, Bunting KV, Gill SK, et al. Redefining β-blocker response in heart failure patients with sinus rhythm and atrial fibrillation: a machine learning cluster analysis. Lancet. 2021. PMID: 34474011. doi:10.1016/S0140-6736(21)01638-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。